Enhanced plasma miR‑26a‑5p promotes the progression of bladder cancer via targeting PTEN

Wang,Hui; Hu,Zhao; Chen,Li

doi:10.3892/ol.2018.9163

Enhanced plasma miR‑26a‑5p promotes the progression of bladder cancer via targeting PTEN

Authors:
- Hui Wang
- Zhao Hu
- Li Chen
View Affiliations

Affiliations: Department of Nephrology, Qilu Hospital, Shandong University, Jinan, Shandong 250014, P.R. China, Department of Endocrinology, Qilu Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: July 17, 2018 https://doi.org/10.3892/ol.2018.9163
Pages: 4223-4228
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to evaluate the expression and specific role of miR‑26a‑5p in the progression of bladder cancer (BC). Reverse transcription‑quantitative polymerase chain reaction analysis was performed to evaluate the level of miR‑26a‑5p in BC cancer and healthy controls. The present data showed that plasma miR‑26a‑5p was significantly increased in BC patients. Furthermore, BC tissues exhibited greater levels of miR‑26a‑5p compared with adjacent non‑neoplastic tissues‑26a‑5p. Compared with BC patients at Ta‑T1 stage, the level of miR‑26a‑5p was significantly elevated in BC patients ≥T2. BC patients at G3 stage demonstrated a higher plasma miR‑26a‑5p level compared with those at G1/2 stage. Receiver operating characteristic (ROC) analysis indicated that miR‑26a‑5p could differentiate BC patients from controls. Additionally, Kaplan‑Meier analysis demonstrated that plasma miR‑26a‑5p negatively correlated with survival of BC patients. Dual luciferase reporter assay indicated that miR‑26a‑5p significantly suppressed the relative luciferase activity of pmirGLO‑PTEN‑3'UTR compared with the control. In conclusion, the current study indicated novel data that the levels of plasma miR‑26a‑5p was significantly increased in BC patients. Furthermore, the present study suggested that determination of plasma miR‑26a‑5p level could help to distinguish BC patients from healthy controls via targeting PTEN.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
3	Latini DM, Lerner SP, Wade SW, Lee DW and Quale DZ: Bladder cancer detection, treatment and outcomes: Opportunities and challenges. Urology. 75:334–339. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, et al: Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers. Urology. 66:35–63. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kaymaz E, Ozer E, Unverdi H and Hucumenoglu S: Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis. Indian J Pathol Microbiol. 60:510–514. 2017. View Article : Google Scholar : PubMed/NCBI
6	Wang Z, Wang X, Zhang D, Yu Y, Cai L and Zhang C: Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer. Tumour Biol. 39:10104283177099902017.PubMed/NCBI
7	Peng F, Li H, Xiao H, Li L, Li Y and Wu Y: Identification of a three miRNA signature as a novel potential prognostic biomarker in patients with bladder cancer. Oncotarget. 8:105553–105560. 2017. View Article : Google Scholar : PubMed/NCBI
8	Duan R, Zhang Z, Zheng F, Wang L, Guo J, Zhang T, Dai X, Zhang S, Yang D, Kuang R, et al: Combining protein and mirna quantification for bladder cancer analysis. ACS Appl Mater Interfaces. 9:23420–23427. 2017. View Article : Google Scholar : PubMed/NCBI
9	Feng C, Sun P, Hu J, Feng H, Li M, Liu G, Pan Y and Feng Y, Xu Y, Feng K and Feng Y: miRNA-556-3p promotes human bladder cancer proliferation, migration and invasion by negatively regulating DAB2IP expression. Int J Oncol. 50:2101–2112. 2017. View Article : Google Scholar : PubMed/NCBI
10	Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 7:e510562012. View Article : Google Scholar : PubMed/NCBI
11	Zhao X, He W, Li J, Huang S, Wan X, Luo H and Wu D: MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354. 2015.PubMed/NCBI
12	Zeng T, Peng L, Chao C, Fu B, Wang G, Wang Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder cancer by regulating EMT. Int J Clin Exp Pathol. 7:7653–7662. 2014.PubMed/NCBI
13	Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep. 5:104372015. View Article : Google Scholar : PubMed/NCBI
14	Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, et al: Circulating tumor cells as potential biomarkers in bladder cancer. J Urol. 194:790–798. 2015. View Article : Google Scholar : PubMed/NCBI
15	Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC and Ellinger J: Circulating microRNAs in serum: Sovel biomarkers for patients with bladder cancer? World J Urol. 32:353–358. 2014. View Article : Google Scholar : PubMed/NCBI
16	Jin Q, Li XJ and Cao PG: miR-26b enhances radiosensitivity of hepatocellular carcinoma cells by targeting EphA2. Iran J Basic Med Sci. 19:851–857. 2016.PubMed/NCBI
17	Gasque Schoof CR, Izzotti A, Jasiulionis MG and Vasques Ldos R: The roles of miR-26, miR-29 and miR-203 in the silencing of the epigenetic machinery during melanocyte transformation. Biomed Res Int. 2015:6347492015. View Article : Google Scholar : PubMed/NCBI
18	Yang F, Wang H, Jiang Z, Hu A, Chu L, Sun Y and Han J: MicroRNA19a mediates gastric carcinoma cell proliferation through the activation of nuclear factor-κB. Mol Med Rep. 12:5780–5786. 2015. View Article : Google Scholar : PubMed/NCBI
19	Wadhwa N, Jatawa SK and Tiwari A: Republished: Non-invasive urine based tests for the detection of bladder cancer. Postgrad Med J. 89:352–357. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wadhwa N, Jatawa SK and Tiwari A: Non-invasive urine based tests for the detection of bladder cancer. J Clin Pathol. 65:970–975. 2012. View Article : Google Scholar : PubMed/NCBI
21	Rossi R, Lichtner M, Iori F, Ermocida A, Mascia C, Mengoni F, Sauzullo I, Dini D, Mastroianni CM and Vullo V: Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. Arch Ital Urol Androl. 85:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
22	Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M and Lopez-Beltran A: Mirna expression in bladder cancer and their potential role in clinical practice. Curr Drug Metab. 18:712–722. 2017. View Article : Google Scholar : PubMed/NCBI
23	Blick C, Ramachandran A, McCormick R, Wigfield S, Cranston D, Catto J and Harris AL: Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis. Br J Cancer. 113:634–644. 2015. View Article : Google Scholar : PubMed/NCBI
24	Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P and Berindan-Neagoe I: Clinical and pathological implications of miRNA in bladder cancer. Int J Nanomedicine. 10:791–800. 2015. View Article : Google Scholar : PubMed/NCBI
25	Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu X, Zhan B, Piao C and Jiang Z: miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression. Oncotarget. 7:48547–48561. 2016. View Article : Google Scholar : PubMed/NCBI
26	Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K: The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mundhenk J, Hennenlotter J, Zug L, Alloussi SH, Todenhoefer T, Gakis G, Aufderklamm S, Scharpf M, Kuehs U, Stenzl A and Schwentner C: Evidence for PTEN-independent Akt activation and Akt-independent p27 (Kip1) expression in advanced bladder cancer. Oncol Lett. 2:1089–1093. 2011. View Article : Google Scholar : PubMed/NCBI
29	Chang N, Lee HW, Lim JE, Jeong DE, Song HJ, Kim S, Nam DH, Sung HH, Jeong BC, Seo SI, et al: Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion. Oncotarget. 7:51626–51639. 2016. View Article : Google Scholar : PubMed/NCBI